Alba Therapeutics Corporation Announces the Next Clinical Trial of Its Lead Compound, Larazotide Acetate and Promotions
... with broad training in basic and clinical
immunology and a vocation for clinical development in the ... was a Director of Clinical Discovery, Oncology/
immunology at Bristol-Myers Squibb where he worked on ... disease. He completed a residency in Clinical
immunology at Ramon y Cajal Hospital, Madrid where he was ...
IBT Laboratories to Launch New Pneumococcal Antibody Avidity Test at AAAAI Meeting, Booth 729
... biomedical-research laboratory specializing in
immunology and allergy assays, will launch a new diagnostic ... of the American Academy of Allergy, Asthma, and
immunology (AAAAI), which opens tomorrow in Washington, DC. ...
IBT offers the widest range of allergy and
immunology tests of any laboratory worldwide. The company ...
IBT Laboratories Expands its Menu of Tests for Immune Deficiency
... biomedical-research laboratory specializing in
immunology and allergy assays, announced that it has ... of the American College of Allergy Asthma and
immunology in Seattle.
According to IBT Founder ... with much greater insight into a patient's
immunology profile than was possible before. "We rely on our ...
Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
... Senior Vice President of Research,
Cellular
immunology of CEL-SCI, indicate that CEL-SCI's ... for the first 14 days (for the histopathology
and
immunology studies) or every other day over the entire study period of
28 days (for the
immunology studies only).
Dr. Zimmerman reported ...
Leading Immunologists Convene in Boston
... Annual meeting of the Federation of Clinical
immunology Societies opens
June 5
BOSTON, June 2 ... 8th annual meeting of
the Federation of Clinical
immunology Societies (FOCIS), June 5-9 at the
Boston ... which can lead to better therapies.
"As the
immunology field rapidly advances in clinical trials and ...
New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly
... 1 American Academy of Allergy Asthma &
immunology Topic of the Month: March 2007: Spring & ... 2007. 2 American Academy of Allergy Asthma &
immunology Tips to Remember: Rhinitis. Available at ... 6 American Academy of Allergy Asthma &
immunology Tips to Remember: Rhinitis. Available at ...
Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
... Phase III study and Associate Professor of Medicine, Division of Clinical
immunology and Rheumatology, and Director, University Clinical Research Center, ... of innovative medicines with a focus on central nervous system and
immunology disorders. Employing around 10,000 people in over 40 countries, UCB ...
Corgenix, Tulane Announce Award of NIH Grant Extending Hemorrhagic Fever Virus Product Development Program
... person-to-person.
Robert Garry, Ph.D., Professor of Microbiology and
immunology at the Tulane University School of Medicine and Principle Investigator ... in the development and manufacturing of specialized diagnostic kits for
immunology disorders, vascular diseases, bone and joint disorders. Corgenix ...
New Study Shows Probiotic Strain Effective in Boosting Immune Response to Flu Virus
... current study.
Dr. Gary Huffnagle, a professor of microbiology and
immunology at the University of Michigan , who has reviewed the study's findings, ... Ken Alibek, M.D., Ph.D., Sc.D., an infectious disease, microbiology, and
immunology expert who has studied Bacillus coagulans extensively, believes that the ...
Changing Paradigms in Hereditary Angioedema: A Focus on Prompt Diagnosis and New Therapies
... and pharmacists.
The faculty for these lectures comprises experts in
immunology and HAE from leading medical institutions. The chairperson is Bruce L. Zuraw, MD, Professor of Medicine and Chief of the Section of Allergy and
immunology at the University of California School of Medicine in San Diego, CA.
...
Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
... or information. Such factors include, among others, the
possibility that
immunology responses may not be a predictor of clinical
benefit; that immunological ... or information contained in this press release include, among
others, that
immunology responses are a predictor of clinical benefit; that
immunological findings ...
Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
... Tuberculosis Vaccine Initiative (SATVI) present a progress update
and
immunology data from a Phase I Ad35 tuberculosis vaccine study at the
biennial ... are amongst the highest in
the world. SATVI has a state of the art
immunology laboratory located at
UCT, where the complex assays needed for TB vaccine ...
Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
... or information. Such factors include, among others, the
possibility that
immunology responses may not be a predictor of clinical
benefit; that immunological ... or information contained in this press release include, among
others, that
immunology responses are a predictor of clinical benefit; that
immunological findings ...
Bristol-Myers Squibb, New Jersey Children's Hospital Launch Center for Immune System Disorders & Infectious Diseases Including HIV/AIDS
... with this debilitating disease."
The new infectious disease and
immunology center is the latest example
of the company's support for the New ... Squibb's SECURE THE FUTURE
The new Pediatric Infectious Disease and
immunology Center is also an
example of Bristol-Myers Squibb's efforts to fight the ...
CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
... by Dr. Daniel H.
Zimmerman, Senior Vice President of Research, Cellular
immunology at
CEL-SCI and involved a collaboration with scientists at several ... including Drs. Kenneth S. Rosenthal Professor of Microbiology
and
immunology at Northeastern Ohio Universities Colleges of Medicine and
Pharmacy ...
Intellect Neurosciences, Inc. to Present Data on Alzheimer's Vaccine at 13th International Congress of Immunology Conference
... chimeric peptide vaccine technology
at the 13th International Congress of
immunology on Thursday, August 23,
2007 in Rio de Janeiro, Brazil. Mice immunized ... companies," commented Professor
Benjamin Chain at the Department of
immunology and Molecular Pathology,
Windeyer Institute of Medical Sciences, ...
Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis
... of new information, future events or otherwise.
(i) Wucherpfennig KW, Weiner HL, Hafler DA. T-cell recognition of myelin basic protein.
immunology Today, 1991; 12: 277-282.
(ii) Ransohoff, R.M. Natalizumab for Multiple Sclerosis. New England Journal of Medicine, 2007 Jun; 356; 25: 2622.
...
CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other Influenzas
... virus (HSV) glycoprotein to make a vaccine that induces a defined immune response. Last month Dr. Kenneth S. Rosenthal, Professor of Microbiology,
immunology and Biochemistry at Northeastern Ohio Universities Colleges of Medicine and Pharmacy and colleagues showed that CEL-SCI's L.E.A.P.S. vaccines can ...
Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
... company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and
immunology disorders. Employing approx. 10 000 people in over 40 countries, UCB achieved revenues of 3.6 billion Euro in 2008. UCB is listed on Euronext ...
Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
... company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and
immunology disorders. Employing approximately 10,000 people in over 40 countries, UCB generated revenue of EUR 3.6 billion in 2008. UCB is listed on Euronext ...
Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma
... strong preclinical efficacy
with PCI-32765 in these disease models," said Dr. Mark Genovese, Professor of
Medicine and Co-Chief of the Division of
immunology and Rheumatology at
Stanford University Medical Center and member of Pharmacyclics' Scientific
Advisory Board.
"Despite recent success with ...
Corgenix AspirinWorks(R) Test Recognized in POLYCAP Study at ACC.09
... .
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for
immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic ...
New Study Suggests Cholesterol-Lowering Statins Reduce Severe Asthma Attacks that Result in Hospitalizations and Emergency Room Visits
... N.J., March 14 /PRNewswire-FirstCall/ -- Results of a new study presented at the 2009 Annual Meeting of the American Academy of Asthma, Allergy and
immunology (AAAAI) show dramatic reductions in emergency room (ER) visits and hospitalizations for asthma patients taking cholesterol-lowering statins in ...
DSM Obtains Exclusive World-Wide License for Innovative Drug Delivery Technology
... diseases and at providing general pain relief. MediVas will focus its development efforts on nanoparticle based therapies in oncology,
immunology and on the delivery of nucleic acids.
" Through this deal we bring in the first biodegradable polymer into DSM's Biomedical portfolio, which ...
Scientists Unmask Genetic Markers Associated With Psoriasis
... or too many Th2 cells in relation to other types of T cells may result in disease, including psoriasis.
This new research, together with recent
immunology work by Elder and colleagues, links four psoriasis loci (IL12B, IL23A, IL23R and IL4/IL13) together in a common functional pathway.
...
New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures
... dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and
immunology disorders. Employing approximately 12,000 people in more than 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB is listed on NYSE ...
Cambridge Laboratories Announces Approval of Tetrabenazine in Spain
... dedicated to the research, development and
commercialisation of innovative medicines with a focus on the fields of
central nervous system and
immunology disorders. Employing around 12 000
people in over 40 countries, UCB achieved revenue of 3.6 billion Euro in
2007. UCB is listed on Euronext Brussels ...
Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia
... patients' quality of life," said I.
Jon Russell, M.D., Ph.D., the study's lead investigator and Associate
Professor of Medicine, Division of Clinical
immunology and Rheumatology, and
Director, University Clinical Research Center, University of Texas Health
Science Center at San Antonio.
The 14-week ...
ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
... for laryngeal attacks required
hospitalization or intubation. The findings were presented today at the
American College of Allergy, Asthma and
immunology (ACAAI) 2008 Annual
Meeting in Seattle, WA.
"The open label extension study findings indicated Cinryze was well
tolerated in this study, and ...
Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
... loss, pale sores inside the mouth, tooth discoloration
or loss of enamel, depression, chronic diarrhea or constipation, gas and
abdominal pain. The
immunology and nutritional abnormalities in celiac
disease can potentially result in long- term complications such as
osteoporosis, refractory sprue, small ...
Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids
... treat children aged six through 11 planned
SEATTLE, Nov. 8, 2008 /PRNewswire/ -- Data presented today at the
American College of Allergy, Asthma &
immunology (ACAAI) show that
Xolair(R) (Omalizumab) for Subcutaneous Use significantly reduced asthma
attacks in children aged six through 11 with moderate or ...
Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
... for the relief of symptoms
in patients with symptomatic knee osteoarthritis," said Dr. Marc C.
Hochberg, Head, Division of Rheumatology & Clinical
immunology at the
University of Maryland School of Medicine. "Furthermore, it had similar
efficacy to orally administered diclofenac with fewer ...
CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
... dedicated to the research, development and
commercialization of innovative medicines with a focus on the fields of
central nervous system and
immunology disorders. Employing around 12 000
people in over 40 countries, UCB achieved revenue of 3.6 billion euro in
2007. UCB is listed on Euronext Brussels ...
Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
... sores inside the mouth, tooth discoloration or loss of
enamel, depression, chronic diarrhea or constipation, and abdominal pain
and bloating. The
immunology and nutritional abnormalities in celiac
disease can potentially result in long-term complications such as
osteoporosis, refractory sprue, small ...
CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients
... dedicated to the research, development and
commercialization of innovative medicines with a focus on the fields of
central nervous system and
immunology disorders. Employing around 12 000
people in over 40 countries, UCB achieved revenue of 3.6 billion euro in
2007. UCB is listed on Euronext Brussels ...
Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
... Securities, and has been an analyst in the sector since
2000. Dr. Smith holds a Ph.D. from the University of Oxford with a focus in
Virology,
immunology and Molecular Biology and has published research in
medical journals including Virology.
"We are pleased to welcome Richard to Pharmasset," said ...
CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients
... dedicated to the research, development and
commercialization of innovative medicines with a focus on the fields of
central nervous system and
immunology disorders. Employing around 12,000
people in over 40 countries, UCB achieved revenue of 3.6 billion euro in
2007. UCB is listed on Euronext Brussels ...
DNA Vaccine Developed at the Karmanos Cancer Institute Fights HER2-Positive Cancers
...
GO)
Wei-Zen Wei, Ph.D., professor at the Barbara Ann Karmanos Cancer
Institute and Department of
immunology and Microbiology, Wayne State
University School of Medicine, together with a team of researchers have
been working on a series of cancer-fighting ...
Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
... and effective vaccines quickly and reliably," said Robert
B. Belshe, M.D., Dianna and J. Joseph Adorjan Endowed Professor of
Infectious Diseases and
immunology at the Saint Louis University School of
Medicine, who served on the Data and Safety Monitoring Board for the study.
"Two doses of this novel vaccine ...
Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
... virologic suppression in patients new to antiretroviral
therapy," said Scott Brun, M.D., divisional vice president, Infectious
Diseases and
immunology Development, Global Pharmaceutical Research and
Development, Abbott. "Additionally, the Kaletra tablet formulation is a
convenient HIV treatment ...